Current Status and Potential Therapeutic Strategies for Using Non-coding RNA to Treat Diabetic Cardiomyopathy

Area of Science:

• Cardiology
• Genetics
• Molecular Biology

Background:

• Diabetic cardiomyopathy (DMCM) is a major complication of diabetes, causing significant mortality and morbidity.
• Pathophysiology involves oxidative stress, inflammation, cardiac fibrosis, and impaired heart function (diastolic and systolic dysfunction).
• Current therapeutic strategies for DMCM have limited success, necessitating exploration of novel approaches.

Purpose of the Study:

• To provide a comprehensive review of pre-clinical and clinical studies on non-coding RNAs (ncRNAs) in diabetic cardiomyopathy.
• To highlight the potential of ncRNAs, including micro-RNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), as novel diagnostics and therapeutics.
• To underscore the need for further research into ncRNA mechanisms for developing effective DMCM therapies.

Main Methods:

• Systematic review of existing literature on ncRNAs and diabetic cardiomyopathy.
• Analysis of pre-clinical and clinical studies investigating the role of miRNAs, lncRNAs, and circRNAs.
• Synthesis of current knowledge regarding ncRNA involvement in DMCM pathophysiology and therapeutic potential.

Main Results:

• Emerging evidence indicates that ncRNAs play a significant role in the development and progression of DMCM.
• ncRNAs are being investigated as potential biomarkers for early diagnosis and as therapeutic targets.
• Specific miRNAs, lncRNAs, and circRNAs have been identified with regulatory functions in cardiac fibrosis and dysfunction.

Conclusions:

• ncRNAs represent a promising frontier for understanding and treating diabetic cardiomyopathy.
• Further research into ncRNA mechanisms is crucial for developing innovative diagnostic and therapeutic strategies.
• Targeting ncRNAs may offer new hope for managing diabetic heart disease and improving patient outcomes.